This work is licensed under the Creative Commons Attribution 4.0 International License.
Pompe JC. Over idiopathische hypertrophie van het hart. Vereenigingsverslag van het Genootschap ter bevordering van Natuur-, Genees- en Heelkunde te Amsterdam. Vergadering van de afdeling Geneeskunde, op woensdag 18 November 1931. Ned Tijdschr Geneeskd. 1932;76:304–11.PompeJCOver idiopathische hypertrophie van het hart. Vereenigingsverslag van het Genootschap ter bevordering van Natuur-, Genees- en Heelkunde te Amsterdam19327630411Search in Google Scholar
Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 2006;86(12):1208–20. doi: 10.1038/labinvest.3700484ThurbergBLLynchMaloney CVaccaroCAfonsoKTsaiACBossenEet alCharacterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease2006861212082010.1038/labinvest.370048417075580Open DOISearch in Google Scholar
Hahn A, Schänzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7(13):283. doi: 10.21037/atm.2019.04.70HahnASchänzerALong-term outcome and unmet needs in infantile-onset Pompe disease201971328310.21037/atm.2019.04.70664293431392195Open DOISearch in Google Scholar
van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40. doi: 10.1542/peds.112.2.332vanden Hout HMHopWvanDiggelen OPSmeitinkJASmitGPPoll-TheBTet alThe natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature200311223324010.1542/peds.112.2.33212897283Open DOISearch in Google Scholar
Güngör D, de Vries JM, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34. doi: 10.1186/1750-1172-6-34GüngörDde VriesJMHopWCReuserAJvan DoornPAvan derPloeg ATet alSurvival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy201163410.1186/1750-1172-6-34313550021631931Open DOISearch in Google Scholar
Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671–7. doi: 10.1093/brain/awh384HagemansMLWinkelLPVanDoorn PAHopWJLoonenMCReuserAJet alClinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients2005128Pt 3671710.1093/brain/awh38415659425Open DOISearch in Google Scholar
Lukacs Z, Nieves Cobos P, Wenninger S, Willis TA, Guglieri M, Roberts M, et al. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology. 2016;87(3):295–8. doi: 10.1212/WNL.0000000000002758LukacsZNievesCobos PWenningerSWillisTAGuglieriMRobertsMet alPrevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness2016873295810.1212/WNL.0000000000002758495527327170567Open DOISearch in Google Scholar
Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;14:3–9. doi: 10.1016/j.ymgmr.2017.10.009FukuharaYFujiNYamazakiNHirakiyamaAKamiokaTSeoJHet alA molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan2017143910.1016/j.ymgmr.2017.10.009567140529124014Open DOISearch in Google Scholar
Pompe disease GAA variant database. Available from: http://www.pompevariantdatabase.nl/pompe_mutations_list.php?orderby=aMut_ID1Available fromhttp://www.pompevariantdatabase.nl/pompe_mutations_list.php?orderby=aMut_ID1Search in Google Scholar
Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, et al. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve. 2009;40(1):32–6. doi: 10.1002/mus.21376GoldsteinJLYoungSPChangelaMDickersonGHZhangHDaiJet alScreening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory200940132610.1002/mus.2137619533645Open DOISearch in Google Scholar
Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Methods of diagnosis of patients with Pompe disease: data from the Pompe Registry. Mol Genet Metab. 2014;113(1–2):84–91. doi: 10.1016/j.ymgme.2014.07.014KishnaniPSAmartinoHMLindbergCMillerTMWilsonAKeutzerJMethods of diagnosis of patients with Pompe disease: data from the Pompe Registry20141131–2849110.1016/j.ymgme.2014.07.01425085280Open DOISearch in Google Scholar
Anderson G, Smith VV, Malone M, Sebire NJ. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J Clin Pathol. 2005;58(12):1305–10. doi: 10.1136/jcp.2005.027045AndersonGSmithVVMaloneMSebireNJBlood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre2005581213051010.1136/jcp.2005.027045177078316311352Open DOISearch in Google Scholar
Pascarella A, Terracciano C, Farina O, Lombardi L, Esposito T, Napolitano F, et al. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. J Cell Physiol. 2018;233(8):5829–37. doi: 10.1002/jcp.26365PascarellaATerraccianoCFarinaOLombardiLEspositoTNapolitanoFet alVacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy2018233858293710.1002/jcp.2636529215735Open DOISearch in Google Scholar
Manwaring V, Prunty H, Bainbridge K, Burke D, Finnegan N, Franses R, et al. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J Inherit Metab Dis. 2012;35(2):311–6. doi: 10.1007/s10545-011-9360-2ManwaringVPruntyHBainbridgeKBurkeDFinneganNFransesRet alUrine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases2012352311610.1007/s10545-011-9360-221687968Open DOISearch in Google Scholar
Rairikar MV, Case LE, Bailey LA, Kazi ZB, Desai AK, Berrier KL, et al. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G “late-onset” GAA variant. Mol Genet Metab. 2017;122(3):99–107. doi: 10.1016/j.ymgme.2017.09.008RairikarMVCaseLEBaileyLAKaziZBDesaiAKBerrierKLet alInsight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G “late-onset” GAA variant201712239910710.1016/j.ymgme.2017.09.008572267528951071Open DOISearch in Google Scholar
Yang CF, Liu HC, Hsu TR, Tsai FC, Chiang SF, Chiang CC, et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A. 2014;164A(1):54–61. doi: 10.1002/ajmg.a.36197YangCFLiuHCHsuTRTsaiFCChiangSFChiangCCet alA large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment2014164A154–6110.1002/ajmg.a.3619724243590Open DOISearch in Google Scholar
Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status afects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33. doi: 10.1016/j.ymgme.2009.08.003KishnaniPSGoldenbergPCDeArmeySLHellerJBenjaminDYoungSet alCross-reactive immunologic material status afects treatment outcomes in Pompe disease infants2010991263310.1016/j.ymgme.2009.08.003372134019775921Open DOISearch in Google Scholar
Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160C(1):40–9. doi: 10.1002/ajmg.c.31319BaliDSGoldsteinJLBanugariaSDaiJMackeyJRehderCet alPredicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience2012160C140–910.1002/ajmg.c.31319327807622252923Open DOISearch in Google Scholar
Wang Z, Okamoto P, Keutzer J. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease. Mol Genet Metab. 2014;111(2):92–100. doi: 10.1016/j.ymgme.2013.08.010WangZOkamotoPKeutzerJA new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease201411129210010.1016/j.ymgme.2013.08.01024044919Open DOISearch in Google Scholar
Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–88. doi: 10.1097/01.gim.0000218152.87434. f3. Erratum in: Genet Med. 2006 Jun;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E].KishnaniPSSteinerRDBaliDBergerKByrneBJCaseLEet alPompe disease diagnosis and management guideline2006852678810.1097/01.gim.0000218152.87434f3. Erratum in: Genet Med. 2006 Jun;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E]Open DOISearch in Google Scholar
Musumeci O, la Marca G, Spada M, Mondello S, Danesino C, Comi GP, et al.; Italian GSD II group. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. J Neurol Neurosurg Psychiatry. 2016;87(1):5–11. doi: 10.1136/jnnp-2014-310164MusumeciOla MarcaGSpadaMMondelloSDanesinoCComiGPet alItalian GSD II group. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population201687151110.1136/jnnp-2014-31016425783438Open DOISearch in Google Scholar
Lai CJ, Hsu TR, Yang CF, Chen SJ, Chuang YC, Niu DM. Cognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy. J Child Neurol. 2016;31(14):1617– 21. doi: 10.1177/0883073816665549LaiCJHsuTRYangCFChenSJChuangYCNiuDMCognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy201631141617–2110.1177/088307381666554927655474Open DOISearch in Google Scholar
Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, et al. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr. 2016;169:174.e1–80.e1. doi: 10.1016/j.jpeds.2015.10.078YangCFYangCCLiaoHCHuangLYChiangCCHoHCet alVery early treatment for infantile-onset Pompe disease contributes to better outcomes2016169174e 1–80.e110.1016/j.jpeds.2015.10.078Open DOISearch in Google Scholar
Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621–30. doi: 10.1007/s00415-016-8219-8SchoserBStewartAKantersSHamedAJansenJChanKet alSurvival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis201726446213010.1007/s00415-016-8219-8Open DOISearch in Google Scholar
Bodamer OA, Scott CR, Giugliani R; Pompe Disease Newborn Screening Working Group. Newborn screening for pompe disease. Pediatrics. 2017;140(Suppl 1):S4–13. doi: 10.1542/peds.2016-0280CBodamerOAScottCRGiuglianiRPompe Disease Newborn Screening Working Group. Newborn screening for pompe disease2017140Suppl 1S41310.1542/peds.2016-0280COpen DOISearch in Google Scholar
Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr. 2015;166(4):985.e1-2–91.e1-2. doi: 10.1016/j.jpeds.2014.10.068ChienYHLeeNCChenCATsaiFJTsaiWHShiehJYet alLong-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth20151664985e1-2–91.e1-210.1016/j.jpeds.2014.10.068Open DOISearch in Google Scholar
Kronn DF, Day-Salvatore D, Hwu WL, Jones SA, Nakamura K, Okuyama T, et al. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum. Pediatrics. 2017;140(Suppl 1):S24–45. doi: 10.1542/peds.2016-0280EKronnDFDay-SalvatoreDHwuWLJonesSANakamuraKOkuyamaTet alManagement of confirmed newborn-screened patients with Pompe disease across the disease spectrum2017140Suppl 1S244510.1542/peds.2016-0280EOpen DOISearch in Google Scholar
Kishnani PS, Hwu WL; Pompe Disease Newborn Screening Working Group. Introduction to the newborn screening, diagnosis, and treatment for Pompe disease guidance supplement. Pediatrics. 2017;140(Suppl 1):S1–3. doi: 10.1542/peds.2016-0280BKishnaniPSHwuWLPompe Disease Newborn Screening Working Group. Introduction to the newborn screening, diagnosis, and treatment for Pompe disease guidance supplement2017140Suppl 1S1310.1542/peds.2016-0280BOpen DOISearch in Google Scholar
Thomas R, Kermode AR. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective. Mol Genet Metab. 2019;126(2):83–97. doi: 10.1016/j. ymgme.2018.11.011ThomasRKermodeAREnzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective20191262839710.1016/j.ymgme.2018.11.011Open DOISearch in Google Scholar
Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356(9227):397–8. doi: 10.1016/s0140-6736(00)02533-2Vanden Hout HReuserAJVultoAGLoonenMCCromme-DijkhuisAVander Ploeg ATRecombinant human alpha-glucosidase from rabbit milk in Pompe patients20003569227397810.1016/s0140-6736(00)02533-2Open DOISearch in Google Scholar
Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3(2):132–8. doi: 10.1038/gim200127AmalfitanoABengurARMorseRPMajureJMCaseLEVeerlingDLet alRecombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial200132132810.1038/gim200127Open DOISearch in Google Scholar
Broomfield A, Fletcher J, Davison J, Finnegan N, Fenton M, Chikermane A, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016;39(2):261–71. doi: 10.1007/s10545-015-9898-5BroomfieldAFletcherJDavisonJFinneganNFentonMChikermaneAet alResponse of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy20163922617110.1007/s10545-015-9898-526497565Open DOISearch in Google Scholar
van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362(15):1396–406. doi: 10.1056/NEJMoa0909859vander Ploeg ATClemensPRCorzoDEscolarDMFlorenceJGroeneveldGJet alA randomized study of alglucosidase alfa in late-onset Pompe’s disease201036215139640610.1056/NEJMoa090985920393176Open DOISearch in Google Scholar
Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology. 2017;89(23):2365–73. doi: 10.1212/WNL.0000000000004711KuperusEKruijshaarMEWensSCAde VriesJMFavejeeMMvan derMeijden JCet alLong-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study2017892323657310.1212/WNL.000000000000471129117951Open DOISearch in Google Scholar
Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017;2(16):e94328. doi: 10.1172/jci.insight.94328KaziZBDesaiAKBerrierKLTroxlerRBWangRYAbdul-RahmanOAet alSustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease2017216e9432810.1172/jci.insight.94328562190928814660Open DOISearch in Google Scholar
Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135–42. doi: 10.1038/gim.2011.4MessingerYHMendelsohnNJRheadWDimmockDHershkovitzEChampionMet alSuccessful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease20121411354210.1038/gim.2011.4371122422237443Open DOISearch in Google Scholar
Koeberl DD, Austin S, Case LE, Smith EC, Buckley AF, Young SP, et al. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. FASEB J. 2014;28(5):2171–6. doi: 10.1096/fj.13-241893KoeberlDDAustinSCaseLESmithECBuckleyAFYoungSPet alAdjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease20142852171610.1096/fj.13-24189324443373Open DOISearch in Google Scholar
Chien YH, Hwu WL, Lee NC, Tsai FJ, Koeberl DD, Tsai WH, et al. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease. Mol Genet Metab Rep. 2017;11:31–5. doi: 10.1016/j.ymgmr.2017.04.004ChienYHHwuWLLeeNCTsaiFJKoeberlDDTsaiWHet alAlbuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease20171131510.1016/j.ymgmr.2017.04.004540627528480166Open DOISearch in Google Scholar
NIH. Clinical Trials Database. Available from: www.clinicaltrials.govAvailable fromwww.clinicaltrials.govSearch in Google Scholar
Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase. Sci Transl Med. 2017;9(418):eaam6375. doi: 10.1126/scitranslmed.aam6375PuzzoFColellaPBiferiMGBaliDPaulkNKVidalPet alRescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase2017941810.1126/scitranslmed.aam6375582661129187643Open DOISearch in Google Scholar
Kishnani PS, Koeberl DD. Liver depot gene therapy for Pompe disease. Ann Transl Med. 2019;7(13):288. doi: 10.21037/ atm.2019.05.02KishnaniPSKoeberlDDLiver depot gene therapy for Pompe disease201971328810.21037/atm.2019.05.02664293531392200Open DOISearch in Google Scholar
Ronzitti G, Collaud F, Laforet P, Mingozzi F. Progress and challenges of gene therapy for Pompe disease. Ann Transl Med. 2019;7(13):287. doi: 10.21037/atm.2019.04.67RonzittiGCollaudFLaforetPMingozziFProgress and challenges of gene therapy for Pompe disease201971328710.21037/atm.2019.04.67664294131392199Open DOISearch in Google Scholar
Swift G, Cleary M, Grunewald S, Lozano S, Ryan M, Davison J. Swallow prognosis and follow-up protocol in infantile onset Pompe disease. JIMD Rep. 2017;33:11–7. doi: 10.1007/8904_2016_576SwiftGClearyMGrunewaldSLozanoSRyanMDavisonJSwallow prognosis and follow-up protocol in infantile onset Pompe disease20173311710.1007/8904_2016_576541344927344650Open DOISearch in Google Scholar
Figueroa-Bonaparte S, Llauger J, Segovia S, Belmonte I, Pedrosa I, Montiel E, et al. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study. Sci Rep. 2018;8(1):10898. doi: 10.1038/s41598-018-29170-7Figueroa-BonaparteSLlaugerJSegoviaSBelmonteIPedrosaIMontielEet alQuantitative muscle MRI to follow up late onset Pompe patients: a prospective study2018811089810.1038/s41598-018-29170-7605200230022036Open DOISearch in Google Scholar
Tarallo A, Carissimo A, Gatto F, Nusco E, Toscano A, Musumeci O, et al. microRNAs as biomarkers in Pompe disease. Genet Med. 2019;21(3):591–600. doi: 10.1038/s41436-018-0103-8TaralloACarissimoAGattoFNuscoEToscanoAMusumeciOet almicroRNAs as biomarkers in Pompe disease201921359160010.1038/s41436-018-0103-829997386Open DOISearch in Google Scholar
Carrasco-Rozas A, Fernández-Simón E, Lleixà MC, Belmonte I, Pedrosa-Hernandez I, Montiel-Morillo E, et al. Identification of serum microRNAs as potential biomarkers in Pompe disease. Ann Clin Transl Neurol. 2019;6(7):1214–24. doi: 10.1002/acn3.50800Carrasco-RozasAFernández-SimónELleixàMCBelmonteIPedrosa-HernandezIMontiel-MorilloEet alIdentification of serum microRNAs as potential biomarkers in Pompe disease20196712142410.1002/acn3.50800664963831353854Open DOISearch in Google Scholar
Schüller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160C(1):80–88. doi: 10.1002/ ajmg.c.31322SchüllerAWenningerSStrigl-PillNSchoserBToward deconstructing the phenotype of late-onset Pompe disease2012160C180–8810.1002/ajmg.c.3132222253010Open DOISearch in Google Scholar
Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120(3): 163–72. doi: 10.1016/j.ymgme.2016.12.004ChanJDesaiAKKaziZBCoreyKAustinSHobson-WebbLDet alThe emerging phenotype of late-onset Pompe disease: a systematic literature review201712031637210.1016/j.ymgme.2016.12.00428185884Open DOISearch in Google Scholar
Mori M, Bailey LA, Estrada J, Rehder CW, Li JS, Rogers JG, et al. Severe cardiomyopathy as the isolated presenting feature in an adult with late-onset pompe disease: a case report. JIMD Rep. 2017;31:79–83. doi: 10.1007/8904_2016_563MoriMBaileyLAEstradaJRehderCWLiJSRogersJGet alSevere cardiomyopathy as the isolated presenting feature in an adult with late-onset pompe disease: a case report201731798310.1007/8904_2016_563538864227142047Open DOISearch in Google Scholar
Bernstein DL, Bialer MG, Mehta L, Desnick RJ. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab. 2010;101(2–3):130–3. doi: 10.1016/j.ymgme.2010.06.003.BernsteinDLBialerMGMehtaLDesnickRJPompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy20101012–3130310.1016/j.ymgme.2010.06.00320638881Open DOISearch in Google Scholar
Ajay D, McNamara ER, Austin S, Wiener JS, Kishnani P. Lower urinary tract symptoms and incontinence in children with pompe disease. JIMD Rep. 2016;28:59–67. doi: 10.1007/8904_2015_492AjayDMcNamaraERAustinSWienerJSKishnaniPLower urinary tract symptoms and incontinence in children with pompe disease201628596710.1007/8904_2015_492505919726537578Open DOISearch in Google Scholar
Guevara-Campos J, González-Guevara L, Cauli O. Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease. Neuromuscul Disord. 2019;29(3):192–7. doi: 10.1016/j.nmd.2018.11.013Guevara-CamposJGonzález-GuevaraLCauliO.Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease2019293192710.1016/j.nmd.2018.11.01330595407Open DOISearch in Google Scholar
Hensel O, Hanisch F, Stock K, Stoevesandt D, Deschauer M, Müller T. Morphology and function of cerebral arteries in adults with Pompe disease. JIMD Rep. 2015;20:27–33. doi: 10.1007/8904_2014_385HenselOHanischFStockKStoevesandtDDeschauerMMüllerTMorphology and function of cerebral arteries in adults with Pompe disease201520273310.1007/8904_2014_385437512325614309Open DOISearch in Google Scholar
Quenardelle V, Bataillard M, Bazin D, Lannes B, Wolff V, Echaniz-Laguna A. Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts. J Neurol. 2015;262(2):473–5. doi: 10.1007/s00415-014-7582-6QuenardelleVBataillardMBazinDLannesBWolffVEchaniz-LagunaAPompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts20152622473510.1007/s00415-014-7582-625451853Open DOISearch in Google Scholar
Pena LD, Proia AD, Kishnani PS. Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease. JIMD Rep. 2015;23:45–54. doi: 10.1007/8904_2015_426PenaLDProiaADKishnaniPSPostmortem findings and clinical correlates in individuals with infantile-onset Pompe disease201523455410.1007/8904_2015_426448490025763511Open DOISearch in Google Scholar
Broomfield A, Fletcher J, Hensman P, Wright R, Prunty H, Pavaine J, et al. Rapidly progressive white matter involvement in early childhood: the expanding phenotype of infantile onset Pompe? JIMD Rep. 2018;39:55–62. doi: 10.1007/8904_2017_46BroomfieldAFletcherJHensmanPWrightRPruntyHPavaineJet al201839556210.1007/8904_2017_46595389028726123Open DOISearch in Google Scholar
van Capelle CI, Goedegebure A, Homans NC, Hoeve HL, Reuser AJ, van der Ploeg AT. Hearing loss in Pompe disease revisited: results from a study of 24 children. J Inherit Metab Dis. 2010;33(5):597–602. doi: 10.1007/s10545-010-9144-0vanCapelle CIGoedegebureAHomansNCHoeveHLReuserAJvander Ploeg ATHearing loss in Pompe disease revisited: results from a study of 24 children201033559760210.1007/s10545-010-9144-0294656620596893Open DOISearch in Google Scholar
Kamphoven JH, de Ruiter MM, Winkel LP, Van den Hout HM, Bijman J, De Zeeuw CI, et al. Hearing loss in infantile Pompe’s disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis. 2004;16(1):14–20. doi: 10.1016/j. nbd.2003.12.018KamphovenJHde RuiterMMWinkelLPVanden Hout HMBijmanJDe ZeeuwCIet alHearing loss in infantile Pompe’s disease and determination of underlying pathology in the knockout mouse2004161142010.1016/j.nbd.2003.12.01815207257Open DOISearch in Google Scholar
Ebbink BJ, Poelman E, Aarsen FK, Plug I, Régal L, Muentjes C, et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 2018;60(6):579–86. doi: 10.1111/dmcn.13740EbbinkBJPoelmanEAarsenFKPlugIRégalLMuentjesCet alClassic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain20186065798610.1111/dmcn.1374029573408Open DOISearch in Google Scholar
Spiridigliozzi GA, Keeling LA, Stefanescu M, Li C, Austin S, Kishnani PS. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up. Mol Genet Metab. 2017;121(2):127–37. doi: 10.1016/j. ymgme.2017.04.014SpiridigliozziGAKeelingLAStefanescuMLiCAustinSKishnaniPSCognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up201712121273710.1016/j.ymgme.2017.04.014598583328495044Open DOISearch in Google Scholar
Musumeci O, Marino S, Granata F, Morabito R, Bonanno L, Brizzi T, et al. Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis. Eur J Neurol. 2019;26(3):442–51, e34–5. doi: 10.1111/ ene.13835MusumeciOMarinoSGranataFMorabitoRBonannoLBrizziTet alCentral nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis201926344251e34–510.1111/ene.1383530312517Open DOISearch in Google Scholar
Schneider I, Hensel O, Zierz S. White matter lesions in treated late onset Pompe disease are not different to matched controls. Mol Genet Metab. 2019;127(2):128–31. doi: 10.1016/j. ymgme.2019.05.007SchneiderIHenselOZierzSWhite matter lesions in treated late onset Pompe disease are not different to matched controls201912721283110.1016/j.ymgme.2019.05.00731153821Open DOISearch in Google Scholar
Byrne BJ, Fuller DD, Smith BK, Clement N, Coleman K, Cleaver B, et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Ann Transl Med. 2019;7(13):290. doi: 10.21037/atm.2019.05.56ByrneBJFullerDDSmithBKClementNColemanKCleaverBet alPompe disease gene therapy: neural manifestations require consideration of CNS directed therapy201971329010.21037/atm.2019.05.56664292931392202Open DOISearch in Google Scholar